# NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

> **NCT07178730** · PHASE3 · NOT_YET_RECRUITING · sponsor: **West German Study Group** · enrollment: 765 (estimated)

## Conditions studied

- Breast Cancer
- Triple-negative Breast Cancer

## Interventions

- **DRUG:** Sacituzumab govitecan
- **DRUG:** Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
- **DRUG:** SoC Chemotherapy

## Key facts

- **NCT ID:** NCT07178730
- **Lead sponsor:** West German Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2033-03-31
- **Final completion:** 2033-03-31
- **Target enrollment:** 765 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07178730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07178730, "NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07178730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*